Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Multiple studies have demonstrated that patients with MAFLD are at an increased risk of developing heart failure (HF) compared to those without MAFLD
Tirzepatide and retatrutide may cause slightly higher increases, potentially due to their broader metabolic effects
The benefit
Journal of Primary Care & Community Health
Australia GLP-1 Receptor Agonist Market Size Analysis Market Size (USD Million): 2024: $499.12M 2025: $570.49M 2026: $652.07M 2027: $745.32M 2028: $851.90M 2029: $973.72M 2030: $1,112.97M 2031: $1,272.12M 2032: $1,454.03M 2033: $1,661.96M 2034: $1,899.62M CAGR: 14.30% 2025-34 Australia GLP-1 Receptor Agonist Market Key Drivers and Challenges: Key Market Drivers: Rising Demand for Effective Metabolic Therapies: The growing rates of type 2 diabetes and obesity in Australia are creating a surge in demand for GLP-1 receptor agonists
Theoretical efficacy retention sits around 95% based on area-under-the-curve calculations
US$ 28.68
US$ 28.76
US$ 26.90
US$ 28.76
US$ 23.10
US$ 22.26
US$ 22.46
